Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7922696 | 0.80 | PPARG (0.64) | PPARGDRD4LTA4HALDH1A1RAB9A | |
| SCHEMBL7815659 | 0.80 | PPARG (0.67) | PPARGPPARA | |
| SCHEMBL9005930 | 0.79 | ALDH1A1 (0.50) | PPARGDRD4ALDH1A1KMT2ALMNA | |
| SCHEMBL9005904 | 0.78 | DRD4 (0.46) | PPARGDRD4KMT2ANPC1LMNA | |
| SCHEMBL7926603 | 0.78 | PPARG (0.50) | PPARGPPARA | |
| SCHEMBL7920692 | 0.78 | PPARG (0.50) | PPARGLTA4HKMT2APPARA | |
| SCHEMBL9005955 | 0.77 | ALOX5 (0.47) | PPARGP2RY14DRD4LTA4HKMT2A | |
| SCHEMBL2786491 | 0.76 | PPARG (0.53) | PPARGDRD4PPARA | |
| SCHEMBL9160316 | 0.76 | PPARG (0.42) | PPARGP2RY14DRD4KMT2ALMNA | |
| SCHEMBL7922719 | 0.76 | PPARG (0.48) | PPARGDRD4PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6294580-B1 | FOR THERAPY AND PROPHYLAXIS OF TYPE II OR NON-INSULIN DEPENDENT DIABETES MELLITUS, HYPERGLYCAEMIA, DYSLIPIDEMIA, TYPE II DIABETES, TYPE I DIABETES, HYPERTRIGLYCERIDEMIA, SYNDROME X, INSULIN RESISTANCE, HEART FAILURE | GLAXO WELLCOME INC. | 2001-09-25 | — | — | US | disclosed |
| EP-0888317-B1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LTD (GB) | 2001-09-12 | — | — | EP | disclosed |
| EP-0888317-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997031907-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1997-09-04 | — | — | WO | disclosed |